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The phosphoinositide 3-kinase (PI 3-kinase, PI3K) pathway transduces signals critical for
lymphocyte function. PI3K generates the phospholipid PIP3 at the plasma membrane to
recruit proteins that contain pleckstrin homology (PH) domains – a conserved domain found
in hundreds of mammalian proteins. PH domain–PIP3 interactions allow for rapid signal
propagation and confer a spatial component to these signals. The kinases Akt and Itk are
key PI3K effectors that bind PIP3 via their PH domains and mediate vital processes – such
as survival, activation, and differentiation – in lymphocytes. Here, we review the roles and
regulation of PI3K signaling in lymphocytes with a specific emphasis on Akt and Itk. We
also discuss these and other PH domain-containing proteins as they relate more broadly
to immune cell function. Finally, we highlight the emerging view of PH domains as multifunctional protein domains that often bind both lipid and protein substrates to exert their
effects.
Keywords: PI3K, lymphocyte activation, pleckstrin homology domain, Akt signaling, Itk signaling

LYMPHOCYTE ACTIVATION RECEPTORS SIGNAL THROUGH
CLASS I PI3Ks
Phosphoinositide 3-kinase (PI3K) activation is important for
lymphocyte survival, activation, differentiation, and migration.
Many lymphocyte surface receptors activate class 1 PI3Ks, which
phosphorylate phosphatidyl inositol 4,5-bisphosphate [PI(4,5)P2 ,
PIP2 ] at the D-3 hydroxyl group of the myo-inositol ring to generate phosphatidyl inositol 3,4,5-trisphosphate [PI(3,4,5)P3 , PIP3 ].
Two subclasses, 1A and 1B, are activated by distinct receptor types
(Figure 1). Receptors or signaling adapters that are phosphorylated at YxxM sequence motifs signal though class IA PI3K, which
includes p85α and p85β regulatory subunits and p110α, p110β,
and p110δ catalytic subunits. These receptors include CD19,
CD28, and ICOS co-receptors; IL-2, IL-7, IL-3, IL-15, and GMCSF cytokine receptors (1–6); and receptors coupled to TRIM,
DAP10, and MyD88 adapter proteins (7–11). Receptor ligation
leads to tyrosine phosphorylation at the YxxM motif and subsequent recruitment of PI3K regulatory subunits through one or
both Src homology 2 (SH2) domains. Regulatory subunits are then
phosphorylated by Syk or Jak family tyrosine kinases to trigger
activation of their constitutively associated catalytic subunits (3).
G-protein-coupled receptors (GPCRs) signal through Class 1B
PI3K, which includes p101 regulatory and p110γ catalytic subunits (12). These classic, seven transmembrane domain receptors
include chemokine receptors and signal through heterotrimeric
G proteins, Gα and Gβγ to promote cell migration. GPCR ligation dissociates the Gβγ dimer, allowing its binding to p101
regulatory subunits and subsequent activation of associated p110γ
catalytic subunits. Activation of p110γ catalytic activity can also
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be induced by Ras activation (Ras-GTP) to promote migration of
neutrophils (13).
Although many receptors activate class 1 PI3K, the magnitude
and kinetics of PI3K activation differs greatly among receptors,
depending on ligand binding kinetics and feedback circuitry that
can either amplify or dampen PI3K signaling (14). Additionally,
co-ligation of receptors, such as the T cell receptor (TCR) and the
CD28 co-receptor, can cooperate to potentiate and sustain PI3K
activation and PIP3 generation.

PIP3 ASSOCIATION WITH PLECKSTRIN HOMOLOGY
DOMAINS
PI3K activation induces PIP3 accumulation, which comprises less
than 5% of PIP2 levels and less than 1% of total membrane
lipids (15). Despite its low overall abundance, super-resolution
microscopy has revealed ~100 nm membrane clusters of PIP3
that create high local PIP3 concentrations (16). High affinity and
specificity binding between PIP3 and pleckstrin homology (PH)
domains of PI3K effectors helps to recruit and activate these effectors at the plasma membrane (Figure 2). Like protein–protein
interactions that are induced by phosphorylation, PIP3 interactions with PH domains allow rapid transduction of downstream
signals without new protein synthesis.
The PH domain is an evolutionarily conserved structural fold
found in proteins expressed in organisms ranging from yeast to
mammals (17). The core of the PH domain is a seven-strand
β-barrel that is encoded by approximately 120 amino acids and
is composed of two anti-parallel β sheets and a C-terminal
α helix (Figure 3). The mammalian genome contains roughly
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FIGURE 1 | Activation of class I PI3Ks by YxxM signaling subunits and
GPCRs. Membrane receptors that activate PI3K include CD19, CD28, and
NKG2D co-receptors, cytokine receptors (e.g., IL-2R), G-protein-coupled
receptors (chemokine receptors), and Fcγ receptor I and III. Class IA PI3Ks

are recruited to the plasma membrane through SH2 domain interactions with
phosphorylated YxxM motifs. Class IB PI3Ks are recruited and activated by
direct interaction with the Gβγ subunit following GPCR activation. Activated
PI3K phosphorylates the membrane lipid PI(4,5)P2 to form PI(3,4,5)P3 .

FIGURE 2 | PI(3,4,5)P3 recruits PH domain-containing proteins to the
plasma membrane and regulates diverse cellular responses. PI3K
phosphorylates PI(4,5)P2 to form PI(3,4,5)P3 , which recruits PH
domain-containing signaling proteins to the plasma membrane. PH

domain-containing proteins are activated at the plasma membrane and
mediate important cellular responses such as cytoskeleton rearrangement,
cell growth, proliferation, and survival. PM, plasma membrane; GEF, guanine
nucleotide exchange factor.

300 PH domains found in proteins that perform diverse functions
including cellular activation, cytoskeletal reorganization, vesicular trafficking, and cell cycle control. Approximately, 15% of PH
domains, including Akt and Itk, bind to phosphoinositides with
high specificity and affinity (K d : nanomolar – low micromolar
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range). PH domains generally interact with phosphoinositides
through positively charged lysine and arginine residues within
the basic motif KXn(K/R)XR (18). However, not all PH domains
bind to PIP3 . Several PH domains interact with phosphoinositides
that are selectively enriched in other membrane compartments,
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FIGURE 3 | Crystal structure of Btk PH domain in complex with
Ins(1,3,4,5)P4 (PDB ID: 2Z0P). The PH domain is comprised of a β-barrel
formed by seven β-strands (yellow, 1–7) capped by an α-helix (pink). The
hyper-variable loops of the β-barrel form the binding surface for lipid ligands
such as Ins(1,3,4,5)P4 [top, shown by ball-and-stick model: red (oxygen),
orange (phosphorus), and gray (carbon)].

such as PI4P within the Golgi membrane (19) or PIP2 at the
resting plasma membrane (17). Thus, conveying lipid specificity to PH domains constitutes a key mechanism for spatially
sequestering distinct effector proteins within cells. Regulating the
abundance of lipids either in resting or activated cells controls
basal and induced effector activity. Additionally, regulated production of lipid ligands such as PIP3 within specific membrane
nano-domains can induce polarized activation of downstream
effectors in a robust but transient manner. This is because PIP3
abundance is not only spatial restricted but also finely controlled by receptor-induced PI3K-dependent PIP3 generation and
by phosphatase and tensin homolog deleted on chromosome
10 (PTEN) and SH2 domain-containing inositol 50 -phosphatase
(SHIP) phosphatase-dependent PIP3 metabolism.

PROTEIN PHOSPHATASES INHIBIT PI3K ACTIVATION WHILE
INOSITOL PHOSPHATASES REDUCE PIP3 LEVELS
PI3K signaling is negatively regulated at distinct steps in its signaling cascade by both protein and lipid phosphatases. Protein
tyrosine phosphatases SHP-1 and SHP-2 inhibit PI3K activation
by preventing early receptor signaling and by directly downregulating PI3K activity, the latter of which is accomplished by
de-phosphorylation of phospho-tyrosine residues within signal
adapter proteins and PI3K regulatory subunits (71). Inhibitory
receptors that restrict lymphocyte activation through SHP-1 or
SHP-2 include inhibitory killer-cell immunoglobulin-like receptors (KIR) on NK cells (72), CD22 on B cells (73), and CTLA-4
and PD-1 on T cells (74, 75). Phosphorylated immunoreceptor
tyrosine-based inhibition motifs (ITIM) within the cytoplasmic
domains of KIRs, CD22, and CTLA-4 recruit SHP-1 and SHP-2
to prevent activating signals at the plasma membrane (72, 74, 75).
Persistent T cell activation signals can also be inhibited by SHP-1
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and SHP-2 recruitment to the immunoreceptor tyrosine-based
switch motif (ITSM) in PD-1, an inhibitory receptor expressed
on chronically stimulated T cells (76, 77). For a detailed discussion regarding the requirements of SHP-1 and SHP-2 in T
cell development, differentiation, and effector function, refer to
Ref. (78).
In T cells, CTLA-4 can also directly repress Akt signaling by
recruiting the Ser/Thr phosphatase PP2A (77), which dephosphorylates the T308 (79, 80) and possibly S473 (79), residues required
for Akt activity. Thus, CTLA-4 utilizes a dual approach to antagonize CD28 and PI3K signaling: SHP-2-dependent inhibition of
TCR signaling by CD3ε de-phosphorylation and PP2A-dependent
de-phosphorylation of Akt (74, 77, 81).
Lipid and inositol phosphatases also prevent PI3K effector activation. PTEN and SHIP both dephosphorylate membrane PIP3 .
However, while PTEN converts PIP3 back to its lipid precursor
PI(4,5)P2 to prevent further activation of PI3K effectors, SHIP
converts PIP3 into PI(3,4)P2 , a lipid that retains the ability to
bind the Akt PH domain (82). In the latter case, subsequent
de-phosphorylation of PI(3,4)P2 into PI(3)P by the inositol phosphatase, INPP4B is required to “turn off ” Akt membrane recruitment (83). Inhibitory receptors including FcγIIB on B cells and
mast cells and Ly49A and Ly49C on NK cells contain ITIM motifs
that recruit SHIP through its SH2 domain (84, 85). Membrane
receptors with cytosolic PDZ domains recruit PTEN to control
PIP3 levels. Although the functional significance of PDZ domaincontaining receptors on lymphocyte activation requires additional
investigation, maintaining appropriate PTEN levels is crucial for
the control of immune cell homeostasis and function (86).

GENERAL AND CELL TYPE-SPECIFIC Akt FUNCTIONS
Akt belongs to the AGC family of Serine/Threonine kinases. The
three Akt isoforms are differentially expressed in various cell types
but are 77–83% sequence identical. Akt activity prevents apoptosis,
promotes protein expression, and regulates cellular metabolism
(20–23). Akt mediates these general cellular functions through
direct phosphorylation of RxRxxS*/T* motifs (24) found in a
plethora of cellular targets including forkhead box transcription
factors, TSC2, GSK3, and BAD, which are discussed in detail elsewhere (20). A somatic mutation in Akt that replaces glutamate with
lysine at residue 17 (hereafter referred to as E17K) leads to cellular
transformation and has been identified in human breast, colorectal, and ovarian cancer (25, 26). The E17K mutation is located
in the lipid binding pocket of Akt’s PH domain and dramatically
increases its affinity for membrane lipids, causing constitutive Akt
signaling (27). Ectopic expression of E17K in hematopoietic stem
cells is sufficient to induce development of lymphoblastic T cell
lymphoma within 6–8 weeks following transfer into recipient mice
(28). Similarly, conditional deletion of the Akt targets Foxo1/3/4
in mice leads to development of the same type of lymphomas
15–25 weeks after induction of Foxo deletion (29).
In lymphocytes, Foxo proteins regulate the gene expression
of Rag recombinases, Ikaros, CCR7, IL-7R, TCF7, Eomes, and
Foxp3, which are critical for controlling lymphocyte development,
trafficking, and differentiation (30–37). Akt phosphorylation of
Foxo1 and Foxo3 leads to their degradation and down-regulates
Foxo-dependent gene expression (31, 38). Genetic ablation of
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both Foxo1 and Foxo3 causes a multi-focal autoimmune disease due to defective Foxp3 expression and T regulatory (Treg)
cell specification and function (34). Similarly, retroviral expression of constitutively active myristoylated Akt (myrAkt) in
CD4− CD8− thymocytes impairs Treg development in vivo following intrathymic transfer. Importantly, the inhibitory effect of
myrAkt is on de novo but not established Foxp3 expression (39).
In contrast, broad expression of myrAkt as a transgene under the
control of the CD2 promoter leads to increased regulatory T cell
numbers in vivo and enhanced suppressive activity (40). Interestingly, conventional CD4+ T cells expressing transgenic myrAkt are
less responsive to TGFβ suppression and fail to differentiate into
the Th17 lineage in response to TGFβ and IL-6 in vitro (40).
A proper balance of Akt activity is also required for appropriate CD8+ T cell maturation, effector function, and memory
development (41). Uzel and colleagues recently published a study
on patients with somatic dominant active p110δ (a catalytic subunit of PI3K) expression (42). T cell blasts from these patients
have increased phosphorylation of AKT at T308 and S473, a
decline in Foxo1, increased S6 activation, and glucose uptake.
This hyperactive Akt/mTORC1 axis causes CD8 T cells to proliferate more vigorously, differentiate more readily into effector
cells, and undergo cellular senescence. Sustained Akt activity in
these patients also impairs development of CD8 memory T cells,
which require a metabolic “switch” from glycolysis to fatty acid
oxidation (41, 43). Furthermore, defective CD8 responses result
in recurrent sinopulmonary infections and chronic viremia due to
Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV) infection (42). Cantrell and coworkers published a surprising finding
demonstrating distinct roles for PDK1 and Akt in promoting cellular metabolism and effector responses of CD8 T cells, respectively
(44). T cells expressing a catalytically inactive p110δ or treated
with an Akt inhibitor are defective for Akt T308 phosphorylation.
Akt-defective CD8 T cells proliferate normally in response to IL2 but are unable to express proper lymphoid homing receptors
and cytotoxic effector proteins (44). In contrast, conditional deletion of PDK1, the upstream activator of Akt, leads to defective
glucose uptake and metabolism, resulting in reduced CD8 T cell
proliferation. This indicates that PDK1 promotes proliferation in
an Akt-independent manner (44). It remains to be determined
whether PDK1 and Akt have distinct roles in cell types in which
multiple functions have been attributed to Akt activity.

TEC FAMILY KINASES REGULATE IMMUNE CELL
DEVELOPMENT AND FUNCTION
The Tec family of non-receptor tyrosine kinases, including Tec, Btk,
Itk/Emt/Tsk, Rlk/Txk, and Bmx/Etk, are differentially expressed in
immune cells. Each Tec family member contains an N-terminal
PIP3 -binding PH domain except Rlk, which contains a cysteinestring motif that results in Rlk palmitoylation. In general, Tec
kinases activate PLCγ to trigger Ca2+ and diacylglycerol (DAG)
signaling. Mimicking Ca2+ and DAG activation with the addition
of calcium ionophores and phorbol myristate acetate (PMA) is
sufficient to induce many aspects of lymphocyte activation, differentiation, and effector responses in vitro. The requirement for
Tec kinases in immune functions is apparent from the profound
defects observed in human patients carrying mutations in Tec
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kinases and in mouse models of single and combined Tec kinase
deficiencies.
In 1993, Btk was first identified in patients with X-linked
agammaglobulinemia (XLA), an inherited immunodeficiency disease characterized by profound hypogammaglobulinemia due to
severely decreased B cell numbers (45). XLA patients carry Btk
mutations that prevent the maturation of pro-B cells into pre-B
cells. Pre-B-cell receptor signaling at the pro-B to pre-B transition requires Btk activation by the Src kinase Lyn (46–48). A
Btk mutation database generated from approximately 400 XLA
patients indicates that the majority of missense mutations in the
Btk PH domain are in the putative PIP3 -binding pocket (49–
51). The XLA missense mutants F25S, R28H, T33P, V64F, and
V113D dramatically reduce Btk binding to PIP3 in vitro and disrupt Btk activation in B cells (52, 53). A similar mutation in mice,
R28C also abolishes Btk binding to PIP3 and results in murine
X-linked immunodeficiency (Xid) disease (53). These findings
demonstrate the importance of PI3K-dependent PIP3 generation
for the membrane recruitment and activation of Btk in promoting
B cell receptor signaling during maturation and humoral immune
responses.
While disruption of PIP3 association causes hypo-B-cell
responses, enhanced PIP3 association also leads to B cell dysfunction. The Btk E41K mutant significantly increases Btk PH domain
affinity for phosphoinositides and results in constitutive membrane localization when expressed ectopically in COS-7 cells (52,
53). Btk E41K expression allows cytokine-independent growth of
the pro-B-cell line Y16 (54), demonstrating its gain-of-function
activity. However, mice expressing a Btk E41K transgene controlled
by the MHC class II locus are more severely B cell-deficient than
even Xid mice (55). Lack of IgMhigh cells in the bone marrow suggest that constitutive Btk E41K activation leads to inappropriate
deletion of immature B cells by mimicking strong BCR signals that
promote apoptosis of auto-reactive B cells (55). Thus, appropriate
levels of Btk activation are critical for developmental progression
of B cells, productive B cell activation and differentiation, as well
as deletion of auto-reactive cells.
The first patients identified with Itk mutations were initially
diagnosed with Hodgkin’s lymphoma but subsequently characterized to have an underlying immunodeficiency disease that prevents
control of EBV-induced B cell proliferation (56). Itk-deficient
patients have decreased T cells (57), which are required to control
EBV infection and prevent viral reactivation from latently infected
B cells (58). Detailed characterization of Itk-deficient mice reveals
multiple requirements for Itk during T cell development, differentiation, and function (59, 60). Like Btk in B cells, Itk participates in
proximal antigen receptor signaling and is directly phosphorylated
by a Src family kinase, in this case Lck (61). Activated Itk phosphorylates PLCγ1, which induces IP3 -dependent increased intracellular Ca2+ levels as well as DAG-mediated signaling (59, 62, 63).
Itk is required for efficient CD4+ T cell differentiation toward the
Th2 and Th17 lineages (59). Itk-deficient mice cannot generate
protective Th2 responses in multiple infection models, including
Leishmania major, Nippostrongylus brasiliensis, and Schistosoma
mansoni (59, 64). Defective Th2 differentiation is accompanied by
substantially reduced production of the Th2 cytokines IL-4, IL5, and IL-13 by Itk-deficient T cells (65, 66). Itk is also required
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for optimal production of the Th17 cytokine, IL-17A but not IL17F (67). The selective requirement for Itk in IL-17A production
is mechanistically linked to a requirement for the transcription
factor nuclear factor of activated T cells (NFAT) in IL-17A transcription (64, 67, 68). Prolonged Itk activation maintains cytosolic
Ca2+ levels to promote sustained calcineurin-dependent NFAT
nuclear translocation. Itk deficiency or suboptimal TCR signaling restricts autoimmunity by biasing T cell differentiation from
the Th17 toward the regulatory T cell lineage (69). In addition,
autoimmune organ destruction can be limited by Itk-dependent
control of transendothelial migration and tissue infiltration of
effector T cells (70). Thus, mechanisms that regulate the magnitude and kinetics of Itk activity in T cells are important for
induction of effector functions, specification of appropriate T cell
lineages, and control of T cell trafficking.

SOLUBLE ANALOGS OF PIP3 DIFFERENTIALLY REGULATE PIP3
EFFECTORS
Some PIP3 -binding PH domains can associate with soluble
PIP3 analogs. These include the cytosolic inositol phosphates Ins(1,3,4,5)P4 (IP4 ), Ins(1,2,3,4,5,6)P6 (IP6 ), and 5-PPI(1,2,3,4,6)P5 (IP7 ) that are generated inducibly or constitutively
by distinct inositol kinases (82). The effect of IP4 , IP6 , and
IP7 binding is distinct for different PH domains and cell types
(Figure 4).
The inositol kinases IP3 kinase (Itpk) isoforms A, B, and C,
and inositol polyphosphate multikinase (IPMK) can each generate IP4 by phosphorylating Ins(1,4,5)P3 (IP3 ) at the D-3 hydroxyl
group [reviewed in Ref. (87)]. However, mice deficient in the ubiquitously expressed ItpkC or IPMK isoforms or in the neuronally
enriched ItpkA isoform have no detectable immune abnormalities.

FIGURE 4 | IP4 and IP7 negatively regulate Akt signaling. IP4 and IP7 are
cytosolic PIP3 analogs that are able to associate with the Akt PH domain with
high affinity and can compete with membrane PIP3 . IP4 and IP7 binding has

www.frontiersin.org

Akt and Itk in lymphocytes

In contrast, ItpkB expression is selectively enriched in hematopoietic cells and catalytically activated by the Ca2+ -sensing protein
calmodulin (CaM) following antigen receptor signaling. Analysis
of ItpkB-deficient mice revealed a non-redundant requirement for
ItpkB in lymphocyte development and activation (88–92). ItpkB
deficiency results in severely reduced peripheral T cell numbers
due to an absolute block in positive selection of CD4+ CD8+ thymocytes (88). Defective activation of the Ras/MAP kinase pathway
contributes to the T cell developmental defect (88, 89, 93). However, ItpkB-deficient CD4+ CD8+ thymocytes are also defective in
activation of Itk and its downstream effector PLC γ1 in response to
TCR engagement (93). Itk fails to localize to the plasma membrane
or assemble with the adapter protein LAT in the TCR signalosome of ItpkB-deficient thymocytes, indicating a requirement for
IP4 in promoting Itk interactions (93). Interestingly, addition of
IP4 increases binding of recombinant Itk PH domain to PIP3 coated beads in vitro, suggesting that IP4 may alter Itk PH domain
conformation to enhance PIP3 accessibility (93).
Distinct from its effect on Itk, IP4 suppresses Akt activity by
directly competing with PIP3 for binding to the Akt PH domain
(94). ItpkB-deficient mice develop profound alterations in neutrophil and NK cell functions due to enhanced Akt activity during
their development and activation (94, 95). Addition of membrane
permeable IP4 , but not an isomer, to the myeloid cell line HL-60
disrupts membrane localization of an Akt PH domain fused to
GFP (94). In ItpkB-deficient neutrophils, Akt phosphorylation is
enhanced in response to the bacterial peptide Formyl–Methionyl–
Leucyl–Phenylalanine (fMLP). Enhanced Akt signaling in ItpkBdeficient neutrophils contributes to augmented anti-microbial and
chemotaxis responses (94). The magnitude and kinetics of Akt
phosphorylation are also increased in ItpkB-deficient NK cells

been proposed to dissociate Akt from the plasma membrane to prevent Akt
activation and substrate accessibility. IP4 , Ins(1,3,4,5)P4 ; IP7 ,
5-PP-(1,2,3,4,6)IP5 ; PIP3 , PI(3,4,5)P3 .
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(95). Elevated IFNγ secretion, granule exocytosis, and tumor cell
lysis by ItpkB-deficient NK cells can be suppressed by Akt inhibition (95). Together, these studies indicate that IP4 dampens
Akt activity in neutrophils and NK cells to restrict effector functions. Whether this occurs to shut-off innate functions during the
resolution phase of an immune response or as a check to limit
inflammatory damage remains unclear.
Similar to IP4 , IP7 also competes with PIP3 for binding to the
Akt PH domain and negatively regulates its activity (96). IP7 is generated by pyro-phosphorylation of IP6 at the 5-phosphate group
by IP6 family kinases, IP6Ks (97, 98). While the importance of
IP6K1 in lymphocyte function remains to be determined, analysis of IP6K1-deficient neutrophils demonstrates similar functional
defects as ItpkB-deficient neutrophils. Both deficiencies result in
enhanced fMLP-induced chemotaxis, superoxide production, and
bacterial killing (94, 99). Akt membrane localization and activation are significantly increased in IP6K1-deficient neutrophils
(99). Interestingly, IP7 is readily detectable in resting HL-60 cells
but rapidly decreases upon fMLP stimulation (99). This suggests
that IP7 may act to suppress initial Akt activation while IP4 regulates subsequent Akt activity following its induced production.
Precise regulation of basal and induced IP4 and IP7 levels may
act together to control the magnitude and kinetics of Akt activation in these innate immune cells. Future studies are required to
determine the functional effects of IP4 and IP7 on Akt-dependent
regulation of lymphocyte differentiation and effector responses.
It also remains to be determined whether IP7 acts on other PIP3
effectors in immune cells as it does in Dictyostelium discoideum
(100) or whether selective IP7 binding allows regulation of a
particular subset of PIP3 effectors.
Recently, biochemical and structural analyses of Btk identified a new activating function for the inositol phosphate, IP6
(101). As with PIP3 -containing liposomes, addition of soluble
IP6 induces Btk trans-phosphorylation and activation. However,
IP6 promotes Btk activation by an unconventional mechanism
that is independent of the PIP3 -binding pocket and membrane
recruitment. Analysis of the co-crystal structure of IP6 with the
Btk PH domain reveals an additional peripheral IP6 binding site
sandwiched between two PH modules, termed the Saraste dimer.
Molecular dynamics simulations suggest that IP6 neutralizes electrostatic forces in the monomer that oppose dimer formation.
Mutation of the IP6 peripheral binding site disrupts transient
dimerization and significantly abrogates IP6 -dependent Btk transphosphorylation (101). IP6 -induced Btk activation in solution
represents a new PI3K-independent mechanism for controlling
Btk activity. Considering that IP6 levels are basally high in lymphocytes, it will be important in future studies to determine
whether IP6 contributes to tonic or B cell receptor-induced Btk
function.

PROTEINS INTERACT WITH AND REGULATE THE ACTIVITY
OF PH DOMAIN-CONTAINING PROTEINS
Although the Akt and Itk PH domains specifically bind to PIP3
with (nanomolar) affinities, only ~40 mammalian PH domains
appear to be PIP3 -regulated according to Teruel and colleagues,
who developed a prediction algorithm based on experimental
analyses of 130 mouse PH domains (102). The majority of PH
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domains do not interact with lipids or bind lipids promiscuously
or with low affinity (K d ≥ 10 µM). Furthermore, a growing number of PH domains have been reported to participate in interand/or intra-molecular protein interactions (discussed below).
These findings support a revised view of PH domains as diverse,
multifunctional domains that bind lipids, proteins, or both to
regulate the activity of their parent proteins.
T and B cells induce Ca2+ and DAG-mediated signaling
through PLCγ1- and PLCγ2-mediated cleavage of PIP2 (103, 104).
T cell-specific ablation of PLCγ1 causes defects in thymocyte selection during T cell development, reduced T cell proliferation and
cytokine secretion, and the development of autoimmunity resulting from defective regulatory T cells (104). PLCγ2 plays important
roles in regulating B cells, neutrophils, mast cells, and dendritic
cells (105–107). PLCγ1 and PLCγ2 both contain two PH domains.
The conventional, N-terminal PH domain associates with PIP3
(108); however, the C-terminal PH domain is interrupted by an
intervening amino acid sequence comprising two tandem SH2
domains and an SH3 domain (109, 110). This split PH domain
is also critical for substrate binding (111). The C-terminal half of
the PLCγ1 split PH domain associates with a partial PH domain
in TRPC3 (112, 113), a Ca2+ channel that can mediate Ca2+ entry
in T cells. The formation of this inter-molecular PH-like domain
allows PLCγ1 to bind to its substrate PIP2 and is critical for TRPC3
membrane targeting and surface expression (113). Conversely, the
split PH domain of PLCγ2 interacts with the small GTPase Rac2,
which mediates PLCγ2 activation and localization to the plasma
membrane (114–116).
Pleckstrin homology domains also participate in intramolecular interactions. In resting cells, the Akt PH domain associates with the kinase domain (KD) to maintain a closed conformation in which the activation loop is blocked (117, 118). PIP3
binding to the Akt PH domain exposes the activation loop, allowing T308 and S473 to be accessed and phosphorylated by PDK1
and mTORC2, respectively (119). Phosphorylation of T308 and
S473 fully activates Akt and keeps the activation loop “open” for
substrate docking (117–119). PH domain mutations that disrupt
PH–KD interaction (e.g., L52R and Q79K) result in constitutive
Akt activation (119).
The Dbl family RhoGEF Vav is also regulated by lipid and intramolecular interactions involving its PH domain (Figure 5). Vav
plays crucial roles during T cell and B cell development (120, 121)
and T cell, B cell, neutrophil, and NK cell activation (9, 107, 120–
123). Vav contains a Dbl homology (DH) domain that promotes
the activation of the small GTPase Rac in response to PI3K activation (124, 125). In quiescent cells, Vav1 adopts an auto-inhibitory
conformation, which is stabilized by interactions between its PH,
acidic (Ac), and calponin homology (CH) domains (126, 127). A
truncation mutation of the Vav N-terminal CH domain was shown
to have oncogenic potential (128), highlighting the importance of
these intra-molecular interactions in limiting Vav activity. During T cell activation, Lck phosphorylates tyrosine residues within
the Ac domain to release Vav1 from auto-inhibition (127). PIP3
binding to the PH domain significantly enhances Lck-dependent
Vav1 phosphorylation in vitro (129) and promotes GEF activity
(124, 129, 130) likely through the release of auto-inhibition (131).
Interestingly, PIP2 binding to the Vav1 PH domain inhibits GEF
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FIGURE 5 | PH domain interactions stabilize Vav1 auto-inhibition in
basal state. In the basal state, Vav1 adopts an auto-inhibitory
conformation in which the substrate-docking site within the DH domain is
blocked by interactions with a helix region from the Ac domain. The

interactions between CH, PH, and Ac domains greatly strengthen the
auto-inhibitory conformation (left). During T cell activation, phosphorylation
of the Ac domain by Lck releases the substrate-docking site and allows
GTPase binding (right).

FIGURE 6 | CaM binds the Itk PH domain in a positive feedback loop that
potentiates Itk activity, intracellular Ca2+ release, and IL-17A production.
Binding of Itk to PIP3 promotes Itk activation and the subsequent
phosphorylation and activation of PLC γ1. PLCγ1 cleaves PIP2 to produce DAG
and IP3 , which binds IP3 receptors on the ER. The IP3 receptor is a
ligand-gated Ca2+ channel, and its activation increases Ca2+ levels in the
cytosol. Increased cytosolic Ca2+ activates CaM, which has at least two
effects on T cell activation: (1) Ca2+ /CaM binds to Itk’s PH domain, enhancing

its interaction with PIP3 and Itk activity. (2) Ca2+ /CaM binds to and activates
calcineurin, a phophatase that dephosphorylates NFAT, allowing NFAT
translocation to the nucleus where it drives the transcription of IL-17A. Thus,
CaM binding to Itk’s PH domain completes a positive feedback loop that
potentiates the downstream effects of Itk. PM, plasma membrane; ER,
endoplasmic reticulum; Itk, IL-2-inducible tyrosine/T cell kinase; PLCγ1,
phospholipase C gamma 1; CaM, calmodulin; NFAT, nuclear factor of activated
T cells; IP3 R, IP3 receptor.

activity (129). Thus, distinct lipids bind to the Vav1 PH domain to
promote conformational changes that either reinforce or relieve
its auto-inhibitory state.
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Pleckstrin homology domains can also participate in intermolecular interactions with other proteins. The PH domain of
Dbs, a Cdc42/RhoGEF, associates with Cdc42 through the β3/β4
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loop of its PH domain to improve substrate docking and catalysis
(132). Interestingly, we recently identified the β3/β4 loop of the
Itk PH domain as an important binding site for the ubiquitous
Ca2+ -sensing protein CaM (133). The CaM C-terminal EF hands
bind to the β3/β4 loop of the Itk PH domain at basal intracellular
Ca2+ levels while the CaM N-terminal EF hands engage the β5/β6
loop upon an increase in Ca2+ levels. CaM and PIP3 (but not IP4 )
reciprocally enhance binding of one another to the Itk PH domain
in vitro, suggesting that CaM and PIP3 cooperate to regulate Itk
signaling at the plasma membrane. Pharmacological inhibition
of Ca2+ /CaM activity or mutation of the CaM-binding β3/β4
loop disrupts Itk-dependent activation of PLCγ1 and downstream
Ca2+ responses (133), indicating that CaM participates in a positive feedback loop whereby binding of CaM to the Itk PH domain
enhances further Itk activation and downstream Ca2+ responses.
Importantly, this positive feedback is required for optimal TCRinduced, NFAT-dependent production of the pro-inflammatory
cytokine, IL-17A (133). Thus, CaM represents a novel proteinbinding partner for the Itk PH domain that serves an important function in potentiating T cell pro-inflammatory responses
(Figure 6). It remains to be determined how CaM, PIP3 , and IP4
coordinate to regulate the kinetics and magnitude of Itk activation
and whether they differentially participate in Itk-dependent T cell
activation, differentiation, and effector responses.
Calmodulin has also been reported by Dong and colleagues to
bind the PH domain of Akt family kinases (134). Using short peptide fragments of Akt1 in a pulldown assay, this interaction was
further mapped to the first 42 residues of the Akt1 PH domain.
Although CaM did not directly alter Akt kinase activity, CaM was
reported to reduce the ability of PIP3 to co-precipitate Akt (134),
suggesting that CaM competes with PIP3 to dampen Akt activity.
However, this finding is inconsistent with other published data
demonstrating a requirement for CaM in optimal Akt phosphorylation at T308 and S473 (135, 136). Thus, further investigation
is warranted to clarify the functional significance of CaM binding
to the AKT PH domain and to determine the precise role of this
interaction in lymphocytes.

CONCLUSION
The studies discussed herein highlight the essential yet complex
functions of PH domain-containing proteins in lymphocytes and
other immune cells. It is well established that a subset of PH
domains modulate the function of their parent proteins by binding
to membrane-bound lipids as well as soluble lipid analogs. Furthermore, proteins regulated in this manner, such as the PI3K effector kinases Akt and Itk, are indispensable for immune cell function.
Indeed, mutations that disrupt the lipid-binding capacity of PH
domains are known to result in human disease, a phenomenon
perhaps best demonstrated by the immunologic defects associated with mutations in Tec family kinases. Analogous and unique
pathological processes observed in animal models and in vitro
experiments reinforce the critical role of PH domain-containing
proteins in the immune system. However, evidence increasingly
shows that PH domains also interact with non-lipid substrates,
and these interactions can be cooperative, antagonistic, or completely independent of lipid-binding capacity. The breadth of these
interactions must be elucidated in order to fully understand role of
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PH domain-containing proteins in immune cell function. Thus,
future work should investigate the capacity of PH domains to
interact with multiple substrates, including both lipids and proteins, and should include careful evaluation of how binding of
each substrate affects the binding of others.

ACKNOWLEDGMENTS
This work was supported by NIH grant AI089805 to YH.
REFERENCES
1. Gadina M, Sudarshan C, Visconti R, Zhou YJ, Gu H, Neel BG, et al. The docking
molecule gab2 is induced by lymphocyte activation and is involved in signaling
by interleukin-2 and interleukin-15 but not other common gamma chain-using
cytokines. J Biol Chem (2000) 275:26959–66. doi:10.1074/jbc.M004021200
2. Ward SG, Cantrell DA. Phosphoinositide 3-kinases in T lymphocyte activation.
Curr Opin Immunol (2001) 13:332–8. doi:10.1016/S0952-7915(00)00223-5
3. Koyasu S. The role of PI3K in immune cells. Nat Immunol (2003) 4:313–9.
doi:10.1038/ni0403-313
4. Guthridge MA, Lopez AF. Phosphotyrosine/phosphoserine binary switches:
a new paradigm for the regulation of PI3K signalling and growth factor
pleiotropy? Biochem Soc Trans (2007) 35:250–2. doi:10.1042/BST0350250
5. Swainson L, Kinet S, Mongellaz C, Sourisseau M, Henriques T, Taylor N. IL7-induced proliferation of recent thymic emigrants requires activation of the
PI3K pathway. Blood (2007) 109:1034–42. doi:10.1182/blood-2006-06-027912
6. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune
cells. Annu Rev Immunol (2013) 31:675–704. doi:10.1146/annurev-immunol032712-095946
7. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10
triggers human NK cell-mediated killing via a Syk-independent regulatory
pathway. Nat Immunol (2003) 4:557–64. doi:10.1038/ni929
8. Kolsch U, Arndt B, Reinhold D, Lindquist JA, Juling N, Kliche S, et al. Normal
T cell development and immune functions in TRIM-deficient mice. Mol Cell
Biol (2006) 26:3639–48. doi:10.1128/MCB.26.9.3639-3648.2006
9. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ.
NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate
and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol
(2006) 7:524–32. doi:10.1038/ni1325
10. Koelsch U, Schraven B, Simeoni L. SIT and TRIM determine T cell fate in the
thymus. J Immunol (2008) 181:5930–9. doi:10.4049/jimmunol.181.9.5930
11. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, et al.
TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol (2009)
85:966–77. doi:10.1189/jlb.1208763
12. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol
(2010) 11:329–41. doi:10.1038/nrm2882
13. Andrews S, Stephens LR, Hawkins PT. PI3K class IB pathway in neutrophils.
Sci STKE (2007) 2007:cm3. doi:10.1126/stke.4072007cm2
14. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and crosstalks. Oncogene (2008) 27:5527–41. doi:10.1038/onc.2008.247
15. Insall RH,Weiner OD. PIP3, PIP2, and cell movement – similar messages, different meanings? Dev Cell (2001) 1:743–7. doi:10.1016/S1534-5807(01)00086-7
16. Wang J, Richards DA. Segregation of PIP2 and PIP3 into distinct nanoscale
regions within the plasma membrane. Biol Open (2012) 1:857–62. doi:10.1242/
bio.20122071
17. Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat
Rev Mol Cell Biol (2008) 9:99–111. doi:10.1038/nrm2328
18. Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, et al. Identification and analysis of PH domain-containing targets of phosphatidylinositol
3-kinase using a novel in vivo assay in yeast. EMBO J (1998) 17:5374–87.
doi:10.1093/emboj/17.18.5374
19. De Matteis MA, Di Campli A, Godi A. The role of the phosphoinositides at
the golgi complex. Biochim Biophys Acta (2005) 1744:396–405. doi:10.1016/j.
bbamcr.2005.04.013
20. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell
(2007) 129:1261–74. doi:10.1016/j.cell.2007.06.009
21. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism
and cancer. Cell Cycle (2009) 8:2502–8. doi:10.4161/cc.8.16.9335

March 2015 | Volume 6 | Article 117 | 8

Wang et al.

22. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012) 4:a011189. doi:10.1101/cshperspect.a011189
23. Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation.
Front Immunol (2012) 3:228. doi:10.3389/fimmu.2012.00228
24. Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwag A, et al. Peptide
and protein library screening defines optimal substrate motifs for AKT/PKB.
J Biol Chem (2000) 285:36108–15. doi:10.1074/jbc.M005497200
25. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A
transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
Nature (2007) 448:439–44. doi:10.1038/nature05933
26. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM,
et al. Sequence analysis of mutations and translocations across breast cancer
subtypes. Nature (2012) 486:405–9. doi:10.1038/nature11154
27. Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: glu17lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry (2008) 47:12260–9. doi:10.1021/
bi801683k
28. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in
mice. Blood (2010) 115:1406–15. doi:10.1182/blood-2009-06-229443
29. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineagerestricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 128:309–23. doi:10.1016/j.cell.2006.12.029
30. Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, et al. FOXO1
regulates L-selectin and a network of human T cell homing molecules
downstream of phosphatidylinositol 3-kinase. J Immunol (2008) 181:2980–9.
doi:10.4049/jimmunol.181.5.2980
31. Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, Depinho
RA, et al. Foxo1 links homing and survival of naive T cells by regulating Lselectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 10:176–84.
doi:10.1038/ni.1689
32. Ouyang W, Beckett O, Flavell RA, Li MO. An essential role of the forkheadbox transcription factor Foxo1 in control of T cell homeostasis and tolerance.
Immunity (2009) 30:358–71. doi:10.1016/j.immuni.2009.02.003
33. Merkenschlager M, von Boehmer H. PI3 kinase signalling blocks Foxp3
expression by sequestering foxo factors. J Exp Med (2010) 207:1347–50.
doi:10.1084/jem.20101156
34. Ouyang W, Beckett O, Ma Q, Paik JH, Depinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol
(2010) 11:618–27. doi:10.1038/ni.1884
35. Alkhatib A, Werner M, Hug E, Herzog S, Eschbach C, Faraidun H, et al. FoxO1
induces Ikaros splicing to promote immunoglobulin gene recombination. J Exp
Med (2012) 209:395–406. doi:10.1084/jem.20110216
36. Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1
represses T-bet-mediated effector functions and promotes memory CD8(+) T
cell differentiation. Immunity (2012) 36:374–87. doi:10.1016/j.immuni.2012.
01.015
37. Michelini RH, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of
CD8 memory T cells depends on Foxo1. J Exp Med (2013) 210:1189–200.
doi:10.1084/jem.20130392
38. Hedrick SM. The cunning little vixen: foxo and the cycle of life and death. Nat
Immunol (2009) 10:1057–63. doi:10.1038/ni.1784
39. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de
novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 205:565–74.
doi:10.1084/jem.20071477
40. Pierau M, Engelmann S, Reinhold D, Lapp T, Schraven B, Bommhardt UH.
Protein kinase B/Akt signals impair Th17 differentiation and support natural
regulatory T cell function and induced regulatory T cell formation. J Immunol
(2009) 183:6124–34. doi:10.4049/jimmunol.0900246
41. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY, et al. Signal
integration by Akt regulates CD8 T cell effector and memory differentiation.
J Immunol (2012) 188:4305–14. doi:10.4049/jimmunol.1103568
42. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al.
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol (2014) 15:88–97. doi:10.1038/ni.2771
43. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting
glycolytic metabolism enhances CD8+ T cell memory and antitumor function.
J Clin Invest (2013) 123:4479–88. doi:10.1172/JCI69589

www.frontiersin.org

Akt and Itk in lymphocytes

44. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al.
Protein kinase B controls transcriptional programs that direct cytotoxic T cell
fate but is dispensable for T cell metabolism. Immunity (2011) 34:224–36.
doi:10.1016/j.immuni.2011.01.012
45. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al.
Deficient expression of a B cell cytoplasmic tyrosine kinase in human
X-linked agammaglobulinemia. Cell (1993) 72:279–90. doi:10.1016/00928674(93)90667-F
46. Afar DE, Park H, Howell BW, Rawlings DJ, Cooper J, Witte ON. Regulation of
Btk by Src family tyrosine kinases. Mol Cell Biol (1996) 16:3465–71.
47. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.
Science (1996) 271:822–5. doi:10.1126/science.271.5250.822
48. Niiro H, Clark EA. Regulation of B cell fate by antigen-receptor signals. Nat
Rev Immunol (2002) 2:945–56. doi:10.1038/nri955
49. Vihinen M, Brandau O, Branden LJ, Kwan SP, Lappalainen I, Lester T, et al.
BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic
Acids Res (1998) 26:242–7. doi:10.1093/nar/26.1.242
50. Vihinen M, Kwan S-P, Lester T, Ochs HD, Resnick I, Väliaho J, et al. Mutations of the human BTK gene coding for Bruton tyrosine kinase in X-linked
agammaglobulinemia. Hum Mutat (1999) 13:280–5. doi:10.1002/(SICI)10981004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L
51. Nomura K, Kanegane H, Karasuyama H, Tsukada S, Agematsu K, Murakami
G, et al. Genetic defect in human X-linked agammaglobulinemia impedes a
maturational evolution of pro-B cells into a later stage of pre-B cells in the B
cell differentiation pathway. Blood (2000) 96:610–7.
52. Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton’s tyrosine kinase in immunodeficiency
impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem
(1996) 271:30303–6. doi:10.1074/jbc.271.48.30303
53. Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton’s tyrosine kinase pleckstrin homology domain
visualized in single living cells. J Biol Chem (1999) 274:10983–9. doi:10.1074/
jbc.274.16.10983
54. Li T, Tsukada S, Satterthwaite A, Havlik MH, Park H, Takatsu K, et al. Activation of Bruton’s tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity (1995) 2:451–60. doi:10.1016/10747613(95)90026-8
55. Maas A, Dingjan GM, Grosveld F, Hendriks RW. Early arrest in B cell development in transgenic mice that express the E41K Bruton’s tyrosine kinase
mutant under the control of the CD19 promoter region. J Immunol (1999)
162:6526–33.
56. Huck K, Feyen O, Niehues T, Rüschendorf F, Hübner N, Laws H-J, et al. Girls
homozygous for an IL-2–inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest
(2009) 119:1350–8. doi:10.1172/JCI37901
57. Serwas NK, Cagdas D, Ban SA, Bienemann K, Salzer E, Tezcan I, et al. Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T cell
lymphopenia. Blood (2014) 124:655–7. doi:10.1182/blood-2014-03-564930
58. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol (2011) 29:351–97.
doi:10.1146/annurev-immunol-072710-081639
59. Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. T cell signaling regulated
by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol (2010) 2:a002287.
doi:10.1101/cshperspect.a002287
60. Grasis JA, Tsoukas CD. Itk: the rheostat of the T cell response. J Signal Transduct
(2011) 2011:297868. doi:10.1155/2011/297868
61. Heyeck SD, Wilcox HM, Bunnell SC, Berg LJ. Lck phosphorylates the activation
loop tyrosine of the Itk kinase domain and activates Itk kinase activity. J Biol
Chem (1997) 272:25401–8. doi:10.1074/jbc.272.40.25401
62. Perez-Villar JJ, Kanner SB. Regulated association between the tyrosine kinase
Emt/Itk/Tsk and phospholipase-C gamma 1 in human T lymphocytes.
J Immunol (1999) 163:6435–41.
63. Takesono A, Finkelstein LD, Schwartzberg PL. Beyond calcium: new signaling
pathways for Tec family kinases. J Cell Sci (2002) 115:3039–48.
64. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al.
Impaired NFATc translocation and failure of Th2 development in Itk-deficient
CD4+ T cells. Immunity (1999) 11:399–409. doi:10.1016/S1074-7613(00)
80115-6

March 2015 | Volume 6 | Article 117 | 9

Wang et al.

65. Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper
2 differentiation via negative regulation of T-bet. Immunity (2004) 21:67–80.
doi:10.1016/j.immuni.2004.06.009
66. Au-Yeung BB, Katzman SD, Fowell DJ. Cutting edge: Itk-dependent signals
required for CD4+ T cells to exert, but not gain, Th2 effector function.
J Immunol (2006) 176:3895–9. doi:10.4049/jimmunol.176.7.3895
67. Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby
MR, et al. Differential expression of interleukin-17A and -17F is coupled to T
cell receptor signaling via inducible T cell kinase. Immunity (2009) 31:587–97.
doi:10.1016/j.immuni.2009.07.009
68. Liao XC, Littman DR. Altered T cell receptor signaling and disrupted T cell
development in mice lacking Itk. Immunity (1995) 3:757–69. doi:10.1016/
1074-7613(95)90065-9
69. Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM,
et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med (2014)
211(3):529–43. doi:10.1084/jem.20131459
70. Jain N, Miu B, Jiang JK, Mckinstry KK, Prince A, Swain SL, et al. CD28 and
ITK signals regulate autoreactive T cell trafficking. Nat Med (2013) 19:1632–7.
doi:10.1038/nm.3393
71. Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity.
J Biol Chem (1999) 274:27583–9. doi:10.1074/jbc.274.39.27583
72. Bryceson YT, Ljunggren HG. Arrestin NK cell cytotoxicity. Nat Immunol (2008)
9:835–6. doi:10.1038/ni0808-835
73. Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a
biochemical pathway regulating BCR signaling and selection. Immunity (1998)
8:497–508. doi:10.1016/S1074-7613(00)80554-3
74. Alegre ML, Frauwirth KA, Thompson CB. T cell regulation by CD28 and CTLA4. Nat Rev Immunol (2001) 1:220–8. doi:10.1038/35105024
75. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune
responses: the unique properties of PD-1 and their advantages for clinical
application. Nat Immunol (2013) 14:1212–8. doi:10.1038/ni.2762
76. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2
associate with immunoreceptor tyrosine-based switch motif of programmed
death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 173:945–54. doi:10.4049/
jimmunol.173.2.945
77. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi
SV, et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543–53. doi:10.1128/MCB.25.21.9543-9553.
2005
78. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at
many levels. Immunol Rev (2009) 228:342–59. doi:10.1111/j.1600-065X.2008.
00760.x
79. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, et al. Protein
phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by
inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol
(2004) 24:8778–89. doi:10.1128/MCB.24.19.8778-8789.2004
80. Kuo YC, Huang KY,Yang CH,Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha
regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt.
J Biol Chem (2008) 283:1882–92. doi:10.1074/jbc.M709585200
81. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science (1998) 282:2263–6.
doi:10.1126/science.282.5397.2263
82. Huang YH, Sauer K. Lipid signaling in T cell development and function. Cold
Spring Harb Perspect Biol (2010) 2:a002428. doi:10.1101/cshperspect.a002428
83. Fedele CG, Ooms LM, Ho M, Vieusseux J, O’toole SA, Millar EK, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in
human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 107:22231–6.
doi:10.1073/pnas.1015245107
84. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP
in negative regulation of the immune system by the receptor Fc(gamma)RIIB.
Nature (1996) 383:263–6. doi:10.1038/383263a0
85. Wang JW, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science (2002) 295:2094–7. doi:10.1126/science.1068438

Frontiers in Immunology | T Cell Biology

Akt and Itk in lymphocytes

86. Newton RH, Turka LA. Regulation of T cell homeostasis and responses by pten.
Front Immunol (2012) 3:151. doi:10.3389/fimmu.2012.00151
87. Sauer K, Cooke MP. Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat Rev Immunol (2010) 10:257–71.
doi:10.1038/nri2745
88. Pouillon V, Hascakova-Bartova R, Pajak B, Adam E, Bex F, Dewaste V, et al.
Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development.
Nat Immunol (2003) 4:1136–43. doi:10.1038/ni980
89. Wen BG, Pletcher MT, Warashina M, Choe SH, Ziaee N, Wiltshire T, et al.
Inositol (1,4,5) trisphosphate 3 kinase B controls positive selection of T cells
and modulates Erk activity. Proc Natl Acad Sci U S A (2004) 101:5604–9.
doi:10.1073/pnas.0306907101
90. Marechal Y, Pesesse X, Jia Y, Pouillon V, Perez-Morga D, Daniel J, et al.
Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression
and survival in B cells. Proc Natl Acad Sci U S A (2007) 104:13978–83.
doi:10.1073/pnas.0704312104
91. Miller AT, Sandberg M, Huang YH, Young M, Sutton S, Sauer K, et al. Production of Ins(1,3,4,5)P4 mediated by the kinase Itpkb inhibits store-operated
calcium channels and regulates B cell selection and activation. Nat Immunol
(2007) 8:514–21. doi:10.1038/ni1458
92. Miller AT, Beisner DR, Liu D, Cooke MP. Inositol 1,4,5-trisphosphate 3-kinase
B is a negative regulator of BCR signaling that controls B cell selection and
tolerance induction. J Immunol (2009) 182:4696–704. doi:10.4049/jimmunol.
0802850
93. Huang YH, Grasis JA, Miller AT, Xu R, Soonthornvacharin S, Andreotti AH,
et al. Positive regulation of Itk PH domain function by soluble IP4. Science
(2007) 316:886–9. doi:10.1126/science.1138684
94. Jia Y, Subramanian KK, Erneux C, Pouillon V, Hattori H, Jo H, et al. Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5trisphosphate signaling in neutrophils. Immunity (2007) 27:453–67. doi:10.
1016/j.immuni.2007.07.016
95. Sauer K, Park E, Siegemund S, French AR, Wahle JA, Sternberg L, et al. Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K
signaling. Blood (2013) 121:286–97. doi:10.1182/blood-2012-05-429241
96. Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, et al.
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell (2010) 143:897–910. doi:10.1016/j.cell.2010.11.032
97. Saiardi A, Erdjument-Bromage H, Snowman AM, Tempst P, Snyder SH. Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Curr Biol (1999) 9:1323–6.
doi:10.1016/S0960-9822(00)80055-X
98. Manning BD. Insulin signaling: inositol phosphates get into the Akt. Cell (2010)
143:861–3. doi:10.1016/j.cell.2010.11.040
99. Prasad A, Jia Y, Chakraborty A, Li Y, Jain SK, Zhong J, et al. Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate immunity by
inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signaling. Nat Immunol
(2011) 12:752–60. doi:10.1038/ni.2052
100. Luo HR, Huang YE, Chen JC, Saiardi A, Iijima M, Ye K, et al. Inositol
pyrophosphates mediate chemotaxis in dictyostelium via pleckstrin homology
domain-PtdIns(3,4,5)P3 interactions. Cell (2003) 114:559–72. doi:10.1016/
S0092-8674(03)00640-8
101. Wang Q, Vogan EM, Nocka LM, Rosen CE, Zorn JA, Harrison SC, et al. Autoinhibition of Bruton’s tyrosine kinase (Btk) and activation by soluble inositol
hexakisphosphate. Elife (2015). doi:10.7554/eLife.06074
102. Park WS, Heo WD, Whalen JH, O’rourke NA, Bryan HM, Meyer T, et al. Comprehensive identification of PIP3-regulated PH domains from C. elegans to
H. sapiens by model prediction and live imaging. Mol Cell (2008) 30:381–92.
doi:10.1016/j.molcel.2008.04.008
103. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev
Immunol (2007) 7:690–702. doi:10.1038/nri2152
104. Fu G, Chen Y, Yu M, Podd A, Schuman J, He Y, et al. Phospholipase C{gamma}1
is essential for T cell development, activation, and tolerance. J Exp Med (2010)
207:309–18. doi:10.1084/jem.20090880
105. Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E, et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors.
Immunity (2000) 13:25–35. doi:10.1016/S1074-7613(00)00005-4
106. Wen R, Jou ST, Chen Y, Hoffmeyer A, Wang D. Phospholipase C gamma 2 is
essential for specific functions of Fc epsilon R and Fc gamma R. J Immunol
(2002) 169:6743–52. doi:10.4049/jimmunol.169.12.6743

March 2015 | Volume 6 | Article 117 | 10

Wang et al.

107. Graham DB, Robertson CM, Bautista J, Mascarenhas F, Diacovo MJ, Montgrain
V, et al. Neutrophil-mediated oxidative burst and host defense are controlled
by a Vav-PLCgamma2 signaling axis in mice. J Clin Invest (2007) 117:3445–52.
doi:10.1172/JCI32729
108. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J.
Activation of phospholipase C gamma by PI 3-kinase-induced PH domainmediated membrane targeting. EMBO J (1998) 17:414–22. doi:10.1093/emboj/
17.2.414
109. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C
isozymes. J Biol Chem (1997) 272:15045–8. doi:10.1074/jbc.272.24.15045
110. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev
Biochem (2001) 70:281–312. doi:10.1146/annurev.biochem.70.1.281
111. Kim SK, Wee SM, Chang JS, Kwon TK, Min DS, Lee YH, et al. Point mutations
in the split PLC-gamma1 PH domain modulate phosphoinositide binding.
J Biochem Mol Biol (2004) 37:720–5. doi:10.5483/BMBRep.2004.37.6.720
112. Lemmon MA. Pleckstrin homology domains: two halves make a hole? Cell
(2005) 120:574–6. doi:10.1016/j.cell.2005.02.023
113. van Rossum DB, Patterson RL, Sharma S, Barrow RK, Kornberg M, Gill
DL, et al. Phospholipase Cgamma1 controls surface expression of TRPC3
through an intermolecular PH domain. Nature (2005) 434:99–104. doi:10.
1038/nature03340
114. Piechulek T, Rehlen T, Walliser C, Vatter P, Moepps B, Gierschik P. Isozymespecific stimulation of phospholipase C-gamma2 by Rac GTPases. J Biol Chem
(2005) 280:38923–31. doi:10.1074/jbc.M509396200
115. Walliser C, Retlich M, Harris R, Everett KL, Josephs MB, Vatter P, et al.
Rac regulates its effector phospholipase Cgamma2 through interaction with
a split pleckstrin homology domain. J Biol Chem (2008) 283:30351–62.
doi:10.1074/jbc.M803316200
116. Everett KL, Buehler A, Bunney TD, Margineanu A, Baxendale RW, Vatter P,
et al. Membrane environment exerts an important influence on Rac-mediated
activation of phospholipase Cgamma2. Mol Cell Biol (2011) 31:1240–51.
doi:10.1128/MCB.01408-10
117. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain
interface in PKB/Akt regulation: structural mechanism for allosteric inhibition.
PLoS Biol (2009) 7:e17. doi:10.1371/journal.pbio.1000017
118. Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GP, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode
of kinase inhibition. PLoS One (2010) 5:e12913. doi:10.1371/journal.pone.
0012913
119. Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, et al.
Disruption of PH-kinase domain interactions leads to oncogenic activation
of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 109:19368–73.
doi:10.1073/pnas.1204384109
120. Fischer KD, Zmuldzinas A, Gardner S, Barbacid M, Bernstein A, Guidos C.
Defective T cell receptor signalling and positive selection of Vav-deficient CD4+
CD8+ thymocytes. Nature (1995) 374:474–7. doi:10.1038/374474a0
121. Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, et al.
Compensation between Vav-1 and Vav-2 in B cell development and antigen
receptor signaling. Nat Immunol (2001) 2:548–55. doi:10.1038/88756
122. Turner M, Billadeau DD. VAV proteins as signal integrators for multisubunit immune-recognition receptors. Nat Rev Immunol (2002) 2:476–86.
doi:10.1038/nri840
123. Hall AB, Gakidis MA, Glogauer M, Wilsbacher JL, Gao S, Swat W, et al.
Requirements for Vav guanine nucleotide exchange factors and Rho GTPases
in FcgammaR- and complement-mediated phagocytosis. Immunity (2006)
24:305–16. doi:10.1016/j.immuni.2006.02.005
124. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, et al. Role of substrates
and products of PI 3-kinase in regulating activation of Rac-related guanosine
triphosphatases by Vav. Science (1998) 279:558–60. doi:10.1126/science.279.
5350.558

www.frontiersin.org

Akt and Itk in lymphocytes

125. Ma AD, Metjian A, Bagrodia S, Taylor S, Abrams CS. Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3kinase gamma, a Rac guanosine exchange factor, and Rac. Mol Cell Biol (1998)
18:4744–51.
126. Li P, Martins IR, Amarasinghe GK, Rosen MK. Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol
(2008) 15:613–8. doi:10.1038/nsmb.1428
127. Yu B, Martins IR, Li P, Amarasinghe GK, Umetani J, Fernandez-Zapico
ME, et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell (2010) 140:246–56. doi:10.1016/j.cell.2009.
12.033
128. Kranewitter WJ, Gimona M. N-terminally truncated Vav induces the formation of depolymerization-resistant actin filaments in NIH 3T3 cells. FEBS Lett
(1999) 455:123–9. doi:10.1016/S0014-5793(99)00857-1
129. Das B, Shu X, Day GJ, Han J, Krishna UM, Falck JR, et al. Control of intramolecular interactions between the pleckstrin homology and Dbl homology domains
of Vav and Sos1 regulates Rac binding. J Biol Chem (2000) 275:15074–81.
doi:10.1074/jbc.M907269199
130. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with
guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol (2005) 6:167–80.
doi:10.1038/nrm1587
131. Aghazadeh B, Lowry WE, Huang X-Y, Rosen MK. Structural basis for relief of
autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell (2000) 102:625–33. doi:10.1016/S0092-8674(00)
00085-4
132. Rossman KL, Worthylake DK, Snyder JT, Siderovski DP, Campbell SL, Sondek J. A crystallographic view of interactions between Dbs and Cdc42: pH
domain-assisted guanine nucleotide exchange. EMBO J (2002) 21:1315–26.
doi:10.1093/emboj/21.6.1315
133. Wang X, Boyken SE, Hu J, Xu X, Rimer RP, Shea MA, et al. Calmodulin and
PI(3,4,5)P(3) cooperatively bind to the Itk pleckstrin homology domain to
promote efficient calcium signaling and IL-17A production. Sci Signal (2014)
7:ra74. doi:10.1126/scisignal.2005147
134. Dong B, Valencia CA, Liu R. Ca(2+)/calmodulin directly interacts with the
pleckstrin homology domain of AKT1. J Biol Chem (2007) 282:25131–40.
doi:10.1074/jbc.M702123200
135. Deb TB, Coticchia CM, Dickson RB. Calmodulin-mediated activation of Akt
regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells.
J Biol Chem (2004) 279:38903–11. doi:10.1074/jbc.M405314200
136. Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD. Calmodulin
modulates Akt activity in human breast cancer cell lines. Breast Cancer Res
Treat (2009) 115:545–60. doi:10.1007/s10549-008-0097-z

Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 12 January 2015; accepted: 02 March 2015; published online: 13 March 2015.
Citation: Wang X, Hills LB and Huang YH (2015) Lipid and protein coregulation of PI3K effectors Akt and Itk in lymphocytes. Front. Immunol. 6:117. doi:
10.3389/fimmu.2015.00117
This article was submitted to T Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Wang , Hills and Huang . This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.

March 2015 | Volume 6 | Article 117 | 11

